⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MCRB News
Seres Therapeutics, Inc.
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
globenewswire.com
MCRB
Form 8-K
sec.gov
MCRB
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
globenewswire.com
MCRB
Form 8-K
sec.gov
MCRB
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
globenewswire.com
MCRB
Form 8-K
sec.gov
MCRB
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
MCRB
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
globenewswire.com
MCRB
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
globenewswire.com
MCRB
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
globenewswire.com
MCRB